Press Release November 14, 2019

Goodwin Advises SVB Leerink LLC and Evercore Group LLC on Centogene B.V. $56 Million IPO

The Life Sciences Capital Markets team represented SVB Leerink LLC and Evercore Group LLC as underwriters on Centogene B.V.’s initial public offering of 4,000,000 of its common shares at a price of $14.00 per common share, for gross proceeds of $56.0 million. In addition, Centogene granted the underwriters a 30-day option to purchase up to an additional 600,000 common shares at the public offering price, less underwriting discounts and commissions.

Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. SVB Leerink LLC is a leading investment bank, specializing in healthcare and life sciences. Evercore Group LLC is a premier global independent investment banking advisory firm.

The Goodwin team was led by Michael Maline, Edwin O’Connor, Will Magioncalda, Jennifer Wong, and Kelvin Lin (Corporate); and included Stephanie Philbin and Elizabeth Mulkey (FDA/Regulatory); Roger Cohen, Allyson Maur, and Bryna Shmerling (Healthcare); Duncan Greenhalgh, Megan Gustafson, and Keith Chadwick (IP); and Stephan Kock, Dimitar Morfov, Kira Mueller, Friederike Hellmann, Christina Papadimitriou, and Carolin Keferstein (Goodwin Frankfurt); with invaluable assistance from Ettore Santucci (Opinions); Janet Andolina (Tax).

For more information, read the press release